CGT9486 is an experimental medication being tested in this clinical trial. It is designed to help treat gastrointestinal stromal tumors, which are a type of cancer that occurs in the digestive tract. The goal of this medication is to stop or slow down the growth of cancer cells, making it easier to manage the disease.

Sunitinib is a medication that is already used to treat certain types of cancer, including gastrointestinal stromal tumors. It works by blocking the action of certain proteins that promote the growth of cancer cells. By doing this, sunitinib can help to slow down or stop the progression of the cancer.

Bezuclastinib is another experimental medication being studied in this trial. Like CGT9486, it is aimed at treating gastrointestinal stromal tumors. Bezuclastinib is intended to work by targeting specific pathways in the cancer cells, potentially stopping them from growing and spreading.

Gastrointestinal stromal tumor – Gastrointestinal stromal tumor (GIST) is a type of tumor that occurs in the digestive tract, most commonly in the stomach or small intestine. It originates from special cells in the wall of the gastrointestinal tract known as interstitial cells of Cajal, which are part of the autonomic nervous system and help regulate digestive processes. GISTs can vary in size and may grow slowly or more rapidly, depending on their specific characteristics. As they progress, these tumors can cause symptoms such as abdominal pain, bleeding, or obstruction, depending on their location and size. They may also spread to other parts of the body, such as the liver or the lining of the abdominal cavity. The progression of GISTs is influenced by various factors, including genetic mutations and the biological behavior of the tumor cells.